InvestorsHub Logo
Followers 61
Posts 9563
Boards Moderated 0
Alias Born 03/29/2015

Re: Pyrrhonian post# 32054

Wednesday, 04/01/2015 6:18:47 PM

Wednesday, April 01, 2015 6:18:47 PM

Post# of 700141
Let's be fair to retail shareholders.

It is not so much fickleness as the very real understanding that with companies like NWBO, getting in too early is even worse than getting in too late.

Get in too late and you miss out on the chance to make a huge profit and maybe even overpay a bit.

Get in too early and you get diluted again and again and end up with a reward that is not justified by the risk you took, assuming you end up with anything at all.

If the retail investors have a "give me it" now mentality, this is in large part because NWBO has encouraged this way of thinking only to consistently dash expectations when the moment of truth arrives. The Delay of Phase 3 by a whole year is the biggest example and the failure to release Direct results in March 2015 as promised is the most recent case. Those who have been around longer could cite more.

You cannot blame retail investors from getting fatigued by this kind of consistent over-promising and under-delivering.

In fairness though if NWBO does not have to rely so heavily on Direct.

Since we both agree that DCVax L is good, why doesn't NWBO prioritize finishing up HE reimbursement negotiations?

That would bring revenues in the door and prove DCVax works in the real world which is more important than any trial since trials are simply an imperfect way of simulating real world results.

So what if we have to take a haircut on the price for L?

If we start saving lives in public and start booking revenue in public that changes the whole conversation.

We would still need financing but it would not be dilutive.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News